CD274 and glioblastoma: This study reports for the first time, to the best of our knowledge, the benefits of utilizing 89Zr-DFO-Atezolizumab to non-invasively map PD-L1 expression in newly diagnosed GBM tumors and immune-cell-rich organs over time, and in response to neoadjuvant immunotherapy.